---
document_datetime: 2025-12-25 07:01:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/seffalair-spiromax.html
document_name: seffalair-spiromax.html
version: success
processing_time: 0.12713
conversion_datetime: 2025-12-28 12:09:44.363008
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Seffalair Spiromax

[RSS](/en/individual-human-medicine.xml/67422)

##### Authorised

This medicine is authorised for use in the European Union

salmeterol / fluticasone propionate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Seffalair Spiromax](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-82191)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Seffalair Spiromax is a medicine used for the regular treatment of asthma in adults and adolescents above 12 years of age. It is used in patients whose disease is not adequately controlled despite treatment with a combination of a short-acting beta-2 agonist and inhaled corticosteroid. It contains the active substances salmeterol and fluticasone.

Expand section

Collapse section

## How is Seffalair Spiromax used?

The medicine can only be obtained with a prescription. It is available as an inhalation powder in an inhaler device.

It comes in two strengths, one containing 12.75 micrograms of salmeterol and 100 micrograms of fluticasone and a higher strength (containing 12.75 micrograms of salmeterol and 202 micrograms of fluticasone).

Patients use one inhalation twice a day (one in the morning and one in the evening); the doctor will decide which strength is appropriate (and change it when necessary) based on how severe the asthma is and how well it has been controlled. Once the asthma is controlled doctors should consider changing patients to inhaled corticosteroid alone.

Patients should be shown how to use the inhaler correctly by a doctor or other healthcare professional.

The delivered doses for Seffalair Spiromax are different from other salmeterol / fluticasone containing products. Seffalair Spiromax should therefore not be swapped with other salmeterol / fluticasone containing inhalers.

For more information about using Seffalair Spiromax, see the package leaflet or contact your doctor or pharmacist.

## How does Seffalair Spiromax work?

The two active substances in Seffalair Spiromax are well known and are present in several medicines used to treat asthma, either alone or in combination with other medicines.

Salmeterol is a long-acting beta-2 agonist. It attaches to beta-2 receptors in the muscles of the airways and causes the muscles of the airways to relax and widen, allowing the patient to breathe more easily.

Fluticasone is a corticosteroid. It reduces the activity of the immune system by attaching to receptors in various types of immune cells, blocking the release of substances involved in the inflammation process. This reduces inflammation in the airways and improves the patient's breathing.

## What benefits of Seffalair Spiromax have been shown in studies?

Two main studies in 1,375 patients with asthma have shown that Seffalair Spiromax is effective at improving patients' FEV1 (the maximum volume of air they can breathe out in one second).

In the first study, patients treated with Seffalair Spiromax (containing 12.75 micrograms of salmeterol and 100 micrograms of fluticasone) for 12 weeks had FEV1 increases of 315 ml, compared with 204 ml for patients treated with a comparable dose of inhaled fluticasone, and 53 ml for patients treated with placebo.

In the second study, patients treated with Seffalair Spiromax (containing 12.75 micrograms of salmeterol and 100 micrograms of fluticasone) had FEV1 increases of 271 ml, compared with 119 ml for patients treated with a comparable dose of inhaled fluticasone, and a decrease of 4 ml for patients treated with placebo. For the higher strength Seffalair Spiromax FEV1 increases were 272 ml, compared with 179 ml for patients treated with a comparable dose of inhaled fluticasone.

## What are the risks associated with Seffalair Spiromax?

The most common side effects with Seffalair Spiromax (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), headache, cough and oral candidiasis (thrush, a fungal infection).

For the full list of side effects and restrictions of Seffalair Spiromax, see the package leaflet.

## Why is Seffalair Spiromax authorised in the EU?

Seffalair Spiromax improves breathing in patients with asthma. It contains two active substances which are well known and already marketed as combination inhalers. The safety profile of Seffalair Spiromax is considered similar to that of other similar inhaler medicines. The European Medicines Agency decided that Seffalair Spiromax's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Seffalair Spiromax?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Seffalair Spiromax have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Seffalair Spiromax are continuously monitored. Side effects reported with Seffalair Spiromax are carefully evaluated and any necessary action taken to protect patients.

## Other information about Seffalair Spiromax

Seffalair Spiromax received a marketing authorisation valid throughout the EU on 26 March 2021.

Seffalair Spiromax : EPAR - Medicine overview

Reference Number: EMA/67034/2021

English (EN) (133.38 KB - PDF)

**First published:** 13/04/2021

[View](/en/documents/overview/seffalair-spiromax-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-242)

български (BG) (156.98 KB - PDF)

**First published:**

13/04/2021

[View](/bg/documents/overview/seffalair-spiromax-epar-medicine-overview_bg.pdf)

español (ES) (132.46 KB - PDF)

**First published:**

13/04/2021

[View](/es/documents/overview/seffalair-spiromax-epar-medicine-overview_es.pdf)

čeština (CS) (153.96 KB - PDF)

**First published:**

13/04/2021

[View](/cs/documents/overview/seffalair-spiromax-epar-medicine-overview_cs.pdf)

dansk (DA) (130.82 KB - PDF)

**First published:**

13/04/2021

[View](/da/documents/overview/seffalair-spiromax-epar-medicine-overview_da.pdf)

Deutsch (DE) (135.52 KB - PDF)

**First published:**

13/04/2021

[View](/de/documents/overview/seffalair-spiromax-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.53 KB - PDF)

**First published:**

13/04/2021

[View](/et/documents/overview/seffalair-spiromax-epar-medicine-overview_et.pdf)

ελληνικά (EL) (155.68 KB - PDF)

**First published:**

13/04/2021

[View](/el/documents/overview/seffalair-spiromax-epar-medicine-overview_el.pdf)

français (FR) (133.62 KB - PDF)

**First published:**

13/04/2021

[View](/fr/documents/overview/seffalair-spiromax-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.82 KB - PDF)

**First published:**

13/04/2021

[View](/hr/documents/overview/seffalair-spiromax-epar-medicine-overview_hr.pdf)

italiano (IT) (143.13 KB - PDF)

**First published:**

13/04/2021

[View](/it/documents/overview/seffalair-spiromax-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.46 KB - PDF)

**First published:**

13/04/2021

[View](/lv/documents/overview/seffalair-spiromax-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.31 KB - PDF)

**First published:**

13/04/2021

[View](/lt/documents/overview/seffalair-spiromax-epar-medicine-overview_lt.pdf)

magyar (HU) (155.24 KB - PDF)

**First published:**

13/04/2021

[View](/hu/documents/overview/seffalair-spiromax-epar-medicine-overview_hu.pdf)

Malti (MT) (156.26 KB - PDF)

**First published:**

13/04/2021

[View](/mt/documents/overview/seffalair-spiromax-epar-medicine-overview_mt.pdf)

Nederlands (NL) (132.19 KB - PDF)

**First published:**

13/04/2021

[View](/nl/documents/overview/seffalair-spiromax-epar-medicine-overview_nl.pdf)

polski (PL) (156.49 KB - PDF)

**First published:**

13/04/2021

[View](/pl/documents/overview/seffalair-spiromax-epar-medicine-overview_pl.pdf)

português (PT) (132.95 KB - PDF)

**First published:**

13/04/2021

[View](/pt/documents/overview/seffalair-spiromax-epar-medicine-overview_pt.pdf)

română (RO) (152.01 KB - PDF)

**First published:**

13/04/2021

[View](/ro/documents/overview/seffalair-spiromax-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.21 KB - PDF)

**First published:**

13/04/2021

[View](/sk/documents/overview/seffalair-spiromax-epar-medicine-overview_sk.pdf)

slovenščina (SL) (152.88 KB - PDF)

**First published:**

13/04/2021

[View](/sl/documents/overview/seffalair-spiromax-epar-medicine-overview_sl.pdf)

Suomi (FI) (130.46 KB - PDF)

**First published:**

13/04/2021

[View](/fi/documents/overview/seffalair-spiromax-epar-medicine-overview_fi.pdf)

svenska (SV) (131.33 KB - PDF)

**First published:**

13/04/2021

[View](/sv/documents/overview/seffalair-spiromax-epar-medicine-overview_sv.pdf)

Seffalair Spiromax : EPAR - Risk-management-plan summary

English (EN) (103.76 KB - PDF)

**First published:** 13/04/2021

[View](/en/documents/rmp-summary/seffalair-spiromax-epar-risk-management-plan-summary_en.pdf)

## Product information

Seffalair Spiromax : EPAR - Product information

English (EN) (924.25 KB - PDF)

**First published:** 13/04/2021

**Last updated:** 16/12/2025

[View](/en/documents/product-information/seffalair-spiromax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-477)

български (BG) (1.11 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/bg/documents/product-information/seffalair-spiromax-epar-product-information_bg.pdf)

español (ES) (1018.79 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/es/documents/product-information/seffalair-spiromax-epar-product-information_es.pdf)

čeština (CS) (1.07 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/cs/documents/product-information/seffalair-spiromax-epar-product-information_cs.pdf)

dansk (DA) (1019.81 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/da/documents/product-information/seffalair-spiromax-epar-product-information_da.pdf)

Deutsch (DE) (1.01 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/de/documents/product-information/seffalair-spiromax-epar-product-information_de.pdf)

eesti keel (ET) (1019.81 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/et/documents/product-information/seffalair-spiromax-epar-product-information_et.pdf)

ελληνικά (EL) (1.1 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/el/documents/product-information/seffalair-spiromax-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/fr/documents/product-information/seffalair-spiromax-epar-product-information_fr.pdf)

hrvatski (HR) (1.06 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/hr/documents/product-information/seffalair-spiromax-epar-product-information_hr.pdf)

íslenska (IS) (1007.85 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/is/documents/product-information/seffalair-spiromax-epar-product-information_is.pdf)

italiano (IT) (1 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/it/documents/product-information/seffalair-spiromax-epar-product-information_it.pdf)

latviešu valoda (LV) (1.08 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/lv/documents/product-information/seffalair-spiromax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.08 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/lt/documents/product-information/seffalair-spiromax-epar-product-information_lt.pdf)

magyar (HU) (1.1 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/hu/documents/product-information/seffalair-spiromax-epar-product-information_hu.pdf)

Malti (MT) (1.22 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/mt/documents/product-information/seffalair-spiromax-epar-product-information_mt.pdf)

Nederlands (NL) (1017.96 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/nl/documents/product-information/seffalair-spiromax-epar-product-information_nl.pdf)

norsk (NO) (995.01 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/no/documents/product-information/seffalair-spiromax-epar-product-information_no.pdf)

polski (PL) (1.14 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/pl/documents/product-information/seffalair-spiromax-epar-product-information_pl.pdf)

português (PT) (1 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/pt/documents/product-information/seffalair-spiromax-epar-product-information_pt.pdf)

română (RO) (1.1 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/ro/documents/product-information/seffalair-spiromax-epar-product-information_ro.pdf)

slovenčina (SK) (1.07 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/sk/documents/product-information/seffalair-spiromax-epar-product-information_sk.pdf)

slovenščina (SL) (1.05 MB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/sl/documents/product-information/seffalair-spiromax-epar-product-information_sl.pdf)

Suomi (FI) (1012.64 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/fi/documents/product-information/seffalair-spiromax-epar-product-information_fi.pdf)

svenska (SV) (1013.81 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

16/12/2025

[View](/sv/documents/product-information/seffalair-spiromax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000280812 12/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Seffalair Spiromax : EPAR - All authorised presentations

English (EN) (81.9 KB - PDF)

**First published:** 13/04/2021

[View](/en/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-856)

български (BG) (92.29 KB - PDF)

**First published:**

13/04/2021

[View](/bg/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_bg.pdf)

español (ES) (82.63 KB - PDF)

**First published:**

13/04/2021

[View](/es/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (90.58 KB - PDF)

**First published:**

13/04/2021

[View](/cs/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (82.72 KB - PDF)

**First published:**

13/04/2021

[View](/da/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (83.48 KB - PDF)

**First published:**

13/04/2021

[View](/de/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (81.73 KB - PDF)

**First published:**

13/04/2021

[View](/et/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (98.91 KB - PDF)

**First published:**

13/04/2021

[View](/el/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_el.pdf)

français (FR) (82.99 KB - PDF)

**First published:**

13/04/2021

[View](/fr/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (90.54 KB - PDF)

**First published:**

13/04/2021

[View](/hr/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (83.5 KB - PDF)

**First published:**

13/04/2021

[View](/is/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (81.67 KB - PDF)

**First published:**

13/04/2021

[View](/it/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (99.94 KB - PDF)

**First published:**

13/04/2021

[View](/lv/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (100.73 KB - PDF)

**First published:**

13/04/2021

[View](/lt/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (90.57 KB - PDF)

**First published:**

13/04/2021

[View](/hu/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.44 KB - PDF)

**First published:**

13/04/2021

[View](/mt/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (81.3 KB - PDF)

**First published:**

13/04/2021

[View](/nl/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (83.8 KB - PDF)

**First published:**

13/04/2021

[View](/no/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_no.pdf)

polski (PL) (92.68 KB - PDF)

**First published:**

13/04/2021

[View](/pl/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_pl.pdf)

português (PT) (83.21 KB - PDF)

**First published:**

13/04/2021

[View](/pt/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_pt.pdf)

română (RO) (81.3 KB - PDF)

**First published:**

13/04/2021

[View](/ro/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (99.09 KB - PDF)

**First published:**

13/04/2021

[View](/sk/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (90.31 KB - PDF)

**First published:**

13/04/2021

[View](/sl/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (81.53 KB - PDF)

**First published:**

13/04/2021

[View](/fi/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (82.21 KB - PDF)

**First published:**

13/04/2021

[View](/sv/documents/all-authorised-presentations/seffalair-spiromax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Seffalair Spiromax Active substance

- fluticasone propionate
- salmeterol xinafoate

International non-proprietary name (INN) or common name

- salmeterol
- fluticasone propionate

Therapeutic area (MeSH) Asthma Anatomical therapeutic chemical (ATC) code R03AK06

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting ?? agonists.

## Authorisation details

EMA product number EMEA/H/C/004881 Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 26/03/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Seffalair Spiromax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.34 KB - PDF)

**First published:** 03/04/2025

**Last updated:** 16/12/2025

[View](/en/documents/procedural-steps-after/seffalair-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Seffalair Spiromax : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (114.99 KB - PDF)

**First published:** 23/08/2021

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/seffalair-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Seffalair Spiromax : EPAR - Public assessment report

Adopted

Reference Number: EMA/99377/2021

English (EN) (8.53 MB - PDF)

**First published:** 13/04/2021

[View](/en/documents/assessment-report/seffalair-spiromax-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Seffalair Spiromax

Adopted

Reference Number: EMA/52882/2021

English (EN) (162.83 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-seffalair-spiromax_en.pdf)

#### News on Seffalair Spiromax

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Seffalair Spiromax : EPAR - Product information - tracked changes

English (EN) (488.96 KB - DOCX)

**First published:** 16/12/2025

[View](/en/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-799)

български (BG) (512.4 KB - DOCX)

**First published:**

16/12/2025

[View](/bg/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_bg.docx)

español (ES) (496.35 KB - DOCX)

**First published:**

16/12/2025

[View](/es/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_es.docx)

čeština (CS) (401.32 KB - DOCX)

**First published:**

16/12/2025

[View](/cs/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (418.93 KB - DOCX)

**First published:**

16/12/2025

[View](/da/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (539.88 KB - DOCX)

**First published:**

16/12/2025

[View](/de/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (495.93 KB - DOCX)

**First published:**

16/12/2025

[View](/et/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (512.26 KB - DOCX)

**First published:**

16/12/2025

[View](/el/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_el.docx)

français (FR) (489.73 KB - DOCX)

**First published:**

16/12/2025

[View](/fr/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (505.32 KB - DOCX)

**First published:**

16/12/2025

[View](/hr/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (499.77 KB - DOCX)

**First published:**

16/12/2025

[View](/is/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_is.docx)

italiano (IT) (508.58 KB - DOCX)

**First published:**

16/12/2025

[View](/it/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (515.8 KB - DOCX)

**First published:**

16/12/2025

[View](/lv/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (429.61 KB - DOCX)

**First published:**

16/12/2025

[View](/lt/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (542.2 KB - DOCX)

**First published:**

16/12/2025

[View](/hu/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (529.08 KB - DOCX)

**First published:**

16/12/2025

[View](/mt/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (413.77 KB - DOCX)

**First published:**

16/12/2025

[View](/nl/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (502.87 KB - DOCX)

**First published:**

16/12/2025

[View](/no/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_no.docx)

polski (PL) (531.24 KB - DOCX)

**First published:**

16/12/2025

[View](/pl/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_pl.docx)

português (PT) (496.66 KB - DOCX)

**First published:**

16/12/2025

[View](/pt/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_pt.docx)

română (RO) (509.63 KB - DOCX)

**First published:**

16/12/2025

[View](/ro/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (412.37 KB - DOCX)

**First published:**

16/12/2025

[View](/sk/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (475.92 KB - DOCX)

**First published:**

16/12/2025

[View](/sl/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (519.16 KB - DOCX)

**First published:**

16/12/2025

[View](/fi/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (492.71 KB - DOCX)

**First published:**

16/12/2025

[View](/sv/documents/product-information-tracked-changes/seffalair-spiromax-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 16/12/2025

## Share this page

[Back to top](#main-content)